Amplia Therapeutics Ltd (ASX: ATX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Amplia Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $19.40 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 194.01 million
Earnings per share -0.025
Dividend per share N/A
Year To Date Return -39.39%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Amplia Therapeutics Ltd (ASX: ATX)
Latest News

medical researcher holding laboratory equipment
Share Market News

Why the Amplia (ASX:ATX) share price is rocketing 41% higher today

The Australian pharmaceutical company sees its share price jump after good news on a drug trial.

Read more »

woman in lab coat conducting testing representing biotech
Share Market News

Here’s why the Amplia (ASX:ATX) share price is up 9% today

The Amplia Therapeutics Ltd (ASX: ATX) share price is running 9% higher today following progress on its AM945 inhibitor. Here's…

Read more »

Buy shares
Share Market News

Amplia Therapeutics share price up 16% in 2 days as former Macquarie CEO takes substantial stake

The Amplia Therapetics Ltd (ASX: ATX) share price has risen16% since Tuesday following an announcement that a former Macquarie CEO…

Read more »

US
Share Market News

US congressman resigns over ASX insider trading penny stock scandal

Can you make money in penny stocks?

Read more »

US
Share Market News

ASX Watergate Arrest: The alleged insider trading at Innate Immunotherapeutics Ltd (ASX:IIL)

A US Congressman and former director of Innate Immunotherapeutics Ltd (ASX:IIL) has been arrested for conspiracy to commit securities fraud.

Read more »

Brokers trading shares
⏸️ Investing

Cann Group Ltd is one of 64 new shares added to the All Ordinaries this quarter

Cann Group Ltd (ASX:CAN) shares are one of 64 new additions to the All Ordinaries (Index:^AXAO) (ASX:XAO) this month. Here's…

Read more »

⏸️ Investing

Were these the 3 worst shares on the ASX in 2017?

The iSentia Group Ltd (ASX:ISD) share price was one of three that destroyed the wealth of unlucky shareholders in 2017…

Read more »

winner, loser
⏸️ Investing

These are the 5 biggest losers on the All Ordinaries in the last 12 months

The Quintis Ltd (ASX:QIN) share price is amongst the five biggest losers on the All Ordinaries (Index:^AXAO) (ASX:XAO) over the…

Read more »

ATX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Amplia Therapeutics Ltd

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

ATX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
05 Aug 2022 $0.10 $0.00 0.00% 148,382 $0.10 $0.11 $0.10
04 Aug 2022 $0.10 $-0.02 -17.39% 2,628,148 $0.12 $0.12 $0.10
03 Aug 2022 $0.12 $0.02 20.41% 261,842 $0.10 $0.12 $0.10
02 Aug 2022 $0.10 $0.00 0.00% 201,115 $0.10 $0.10 $0.10
29 Jul 2022 $0.10 $0.00 0.00% 51,124 $0.10 $0.10 $0.10
28 Jul 2022 $0.10 $0.00 0.00% 217,873 $0.10 $0.10 $0.10
27 Jul 2022 $0.09 $0.00 0.00% 50,000 $0.09 $0.09 $0.09
26 Jul 2022 $0.09 $0.00 0.00% 12,537 $0.09 $0.09 $0.09
25 Jul 2022 $0.09 $0.00 0.00% 159,620 $0.09 $0.09 $0.09
22 Jul 2022 $0.09 $0.00 0.00% 370,406 $0.10 $0.10 $0.09
21 Jul 2022 $0.10 $0.00 0.00% 160,110 $0.10 $0.10 $0.10
20 Jul 2022 $0.10 $0.00 0.00% 2,000 $0.10 $0.10 $0.10
19 Jul 2022 $0.10 $0.00 0.00% 4,228 $0.10 $0.10 $0.10
18 Jul 2022 $0.10 $0.00 0.00% 15,026 $0.10 $0.10 $0.10
15 Jul 2022 $0.10 $0.00 0.00% 55,518 $0.10 $0.10 $0.10
14 Jul 2022 $0.10 $0.00 0.00% 10,051 $0.10 $0.10 $0.10
13 Jul 2022 $0.10 $-0.02 -17.39% 371,657 $0.11 $0.11 $0.09
12 Jul 2022 $0.12 $0.01 9.09% 5,649 $0.11 $0.12 $0.11

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
30 Jun 2022 John Lambert Expiry 50 $4,800
Options expired.
30 Jun 2022 Robert Peach Expiry 500 $48,000
Options expired.
30 Jun 2022 Warwick Tong Expiry 165 $15,840
Options expired.
30 Jun 2022 Christopher Burns Expiry 30 $2,880
Options expired.
10 Feb 2022 S Jane Bell Buy 127 $21,613
On-market trade.
09 Feb 2022 S Jane Bell Buy 72 $12,386
On-market trade.
04 Feb 2022 S Jane Bell Buy 22 $3,574
On-market trade.
20 Dec 2021 S Jane Bell Buy 714 $103,571
On-market trade.
15 Dec 2021 Warwick Tong Issued 33 $5,666
Rights issue.
15 Dec 2021 Warwick Tong Issued 100 $18,000
Rights issue.
15 Dec 2021 Christopher Burns Issued 18 $3,148
Rights issue.
15 Dec 2021 Christopher Burns Issued 55 $9,999
Rights issue.
15 Dec 2021 S Jane Bell Issued 69 $12,472
Rights issue.
15 Dec 2021 S Jane Bell Issued 72 $12,340
Rights issue.
15 Dec 2021 S Jane Bell Issued 148 $26,726
Rights issue.
15 Dec 2021 Robert Peach Issued 332 $59,931
Rights issue.
15 Dec 2021 Robert Peach Issued 110 $18,867
Rights issue.
15 Dec 2021 John Lambert Issued 29 $4,958
Rights issue.
15 Dec 2021 John Lambert Issued 32 $5,850
Rights issue.
15 Dec 2021 John Lambert Issued 55 $9,900
Rights issue.
02 Sep 2021 S Jane Bell Buy 557 $115,432
On-market trade.
01 Sep 2021 S Jane Bell Buy 36 $6,890
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Andrew John Cooke Company Secretary Oct 2013
Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.
Dr John Lambert Chief Executive OfficerManaging Director Jun 2019
Dr Lambert was appointed CEO on 24 June 2019 and Managing Director on 6 February 2020. John has more than 18 years of drug discovery and development experience. His prior appointments included leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), primarily working on the development of respiratory antiviral drugs. As a Senior Director at Medicines Development for Global Health, he was a member of the team that received approval in 2018 from the US FDA for moxidectin as a treatment for river blindness. Prior to working in industry he was an academic researcher in organic, medicinal and biological chemistry (University of Melbourne, ANU and Harvard University). He is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.
Dr Robert Peach Non-Executive Director Sep 2015
Dr Peach has 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. In 2009 he co-founded Receptos Limited, becoming Chief Scientific Officer and raising US$59M in venture capital and US$800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for US$7.8B. Dr Peach held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments. His drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is currently on the Board of Directors of AdAlta Limited (1AD) and Rekover Therapeutics, and serves on the Scientific Advisory Board of Eclipse Bioinnovations. Dr Peach is the co-author of 70 scientific publications and book chapters, and 26 patents and patent applications.
Ms S Jane Catherine Bell Non-Executive Director Apr 2021
Mrs Bell has more than 30 years' experience in leading law firms, financial services and corporate treasury operations gained living in Melbourne, London, Toronto, San Francisco and Brisbane. She has been a non-executive director since 2002, serving on 13 boards including nine health and medical research boards. She currently serves as Deputy Chair of Monash Health, Director of Jessie McPherson Private Hospital, Chair of the Community Advisory Group of the Melbourne Genomics Health Alliance and is a Tribunal Member of the Administrative Appeals Tribunal. She is a former Chair of Melbourne Health (Royal Melbourne Hospital), Chair of Biomedical Research Vic, Deputy Chair of Westernport Water Corporation, Director of UCA Funds Management, WorkSafe Victoria, Hudson Institute of Medical Research-Monash Institute of Medical Research Prince Henry's Institute of Medical Research, Queensland Institute of Medical Research Trust, Australian Red Cross (Qld) and Victorian Women's Housing Association.
Dr Warwick Bonner Tong Non-Executive DirectorNon-Executive Chairman May 2018
Dr Tong has more than 25 years' experience in the Pharmaceutical and Biotechnology industry. After his early career in General Medical Practice Warwick has held a wide variety of roles in the pharmaceutical and biotech industry in NZ(Glaxo) Singapore (GlaxoWellcome) London (GSK), Boston (Surface Logix) and Melbourne (CTx - Cancer Therapeutics CRC). Warwick currently serves as director of Aculeus Therapeutics Pty Ltd and of KMT Pharmaceuticals Pty Ltd. He is a member of the Strategic Advisory Board of the Maurice Wilkins Centre in Auckland NZ and of the CSIRO Manufacturing Business Advisory Committee. He is a former CEO and director of CTx, director and Chair of the CTx commercialisation company, CTxONE, and director and Chair of BioMedVic. Je was appointed as a Non-Executive Director on the 4th of May 2018 and Chairman on 25 May 2018.
Dr Christopher John Burns Non-Executive Director May 2018
Dr Burns is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 25 years. He undertook post doctoral studies in the USA before moving to Pfizer UK, where he worked on a variety of drug discovery projects. After 5 years he returned to Australia as a Research Fellow at the University of Sydney with the CRC for Molecular Engineering and Technology and after two years moved to the biotechnology company Ambri as Head of Chemistry. He then moved to the Melbourne based biotech Cytopia as Head of Medicinal Chemistry and later as Research Director. During this time he led teams in the discovery of two anti-cancer drugs that entered clinical trial, including the drug momelotinib which recently successfully completed Phase III studies. He subsequently joined WEHI in Melbourne as a Laboratory Head before taking on senior roles at the biotech start-ups Metabloq Pharmaceuticals, Certa Therapeutics and, most recently, MycRx, where he is now SVP of R&D. Dr Burns is the inventor on over 30 patents and a co-author on over 60 scientific publications and is a Fellow of the Royal Society of Chemistry (UK) and the Royal Australian Chemical Institute.

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Hsbc Custody Nominees (Australia) Limited 36,671,897 18.92%
Bond Street Custodians Limited (Lam1 - D08047 A/C) 13,472,500 6.95%
J P Morgan Nominees Australia Pty Limited 8,419,597 4.34%
Citicorp Nominees Pty Limited 6,541,372 3.37%
Ubs Nominees Pty Ltd 4,132,790 2.13%
Ctxt Pty Ltd 3,940,579 2.03%
Bnp Paribas Noms Pty Ltd 3,769,149 1.94%
Elk River Holdings Pty Ltd 2,942,142 1.52%
Christopher John Burns 2,527,798 1.30%
Gp Securities Pty Ltd 2,412,500 1.24%
Warwick Tong 2,355,140 1.21%
34Th Avenue Pty Ltd 2,215,237 1.14%
Mr Andrew Podolak 1,925,000 0.99%
Mrs Jane Catherine Jocelyn Bell + Mr Geoffrey 1,679,020 0.87%
Arthur Bell (Schooner Super Fund A/C) 1,661,428 0.86%
Mr Mark Sullivan 1,500,000 0.77%
J & J Stuart Pty Ltd 1,459,267 0.75%
Mr Michael Andrew Whiting 1,360,524 0.70%
+ Mrs Tracey Anne Whiting (Whiting Family S/F A/C) 1,359,435 0.70%
Cancer Research Technology Limited 1,350,000 0.70%

Profile

since

Note